  |
 | Up a level |
Rini, Brian I. and Plimack, Elizabeth R. and Stus, Viktor and Waddell, Tom and Gafanov, Rustem and Pouliot, Frédéric and Nosov, Dmitry and Melichar, Bohuslav and Soulieres, Denis and Borchiellini, Delphine and Vynnychenko, Ihor O. and McDermott, Raymond S. and Azevedo, Sergio Jobim and Tamada, Satoshi and Kryzhanivska, Anna and Li, Chenxiang and Burgents, Joseph E. and Molife, L. Rhoda and Bedke, Jens and Powles, Thomas (2021) Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Journal of Clinical Oncology, 39 (15 s.1). p. 4500. ISSN 0732-183X (Print); 1527-7755 (Electronic); 0732-183X (Linking)
Plimack, Elizabeth R. and Rini, Brian I. and Stus, Viktor and Gafanov, Rustem and Waddell, Tom and Nosov, Dmitry and Pouliot, Frédéric and Soulieres, Denis and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L. Rhoda and Atkins, Michael B. and Powles, Thomas (2020) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Journal of Clinical Oncology, Vol.38 (15supp). p. 5001. ISSN 1527-7755 (online, version of record) and 0732-183X (print)
